Working for the

TREATMENT & MANAGEMENT
OF METABOLIC DISEASES.

MEET THE TEAM

ISLET SCIENCES

Changing the Way Diabetes is Treated

MISSION

Islet Sciences’ mission is to improve patient outcomes by transforming great science into actionable solutions for the treatment of metabolic diseases.

Islet Sciences, Inc. is developing new medicines and technologies for the treatment of metabolic diseases.

The Company’s current pipeline includes first in class immune modulating small molecule interleukin 12 inhibitors to address disorders associated with inflammation, a cell therapy based artificial pancreas for the treatment of type 1 diabetes, and a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the early detection of the onset of type 1 diabetes or insulin dependent type 2 diabetes.

THERAPY

IL-12 Antagonists
Islet Sciences is developing first-in-class immune-modulating drugs that protect insulin-producing beta-cells from cytokines responsible for cell destruction. IL-12 and STAT 4 activation are important pathways linked to inflammatory damage to insulin producing cells. Islet Sciences is developing a next generation of orally bioavailable immune modulators against these key targets for the promise of providing a new therapeutic approach to treat type 1 or type 2 diabetes. These compounds were screened in vitro for their ability to provide beta cell protection against cytokines and preservation of insulin secretion. Three Lead compounds have been identified and are being progressed in pre-clinical studies. These next generation compounds will have better oral bioavailability and efficacy than LSF (left), offering the promise of providing a new therapeutic approach to treat type 1 or type 2 diabetes. Additional studies show that C-9 also directly reduces liver fibrosis in a Non-alcoholic Steatohepatitis preclinical model.

TECHNOLOGIES

Islet Sciences is developing Islet Sciences-P™ — a vialed suspension of microencapsulated porcine islets for injection into the abdominal cavity. Islet Sciences-P will be a ready-to-use formulation that will require very little preparation by the transplant surgeon. IS-P is designed to improve microencapsulated islet cell viability and functionality at several points in the preparation of this suspension. We believe our cell handling techniques substantially increase the longevity and functionality of the encapsulated islet cells.

Current treatments for Insulin Dependent Diabetes are palliative and require constant glucose monitoring and repeated daily insulin injections. In contrast, the transplantation of insulin-producing pancreatic islet cells could free patients of monitoring and injections altogether.

A team at the University of Alberta managed to successfully treat diabetes in dozens of patients by transplanting them with human pancreatic islet cells. (New England Journal of Medicine, 343(4): 230-8, 2000) Furthermore, 85% of the original patients remained insulin-free for one year or more following the transplant.

The effectiveness of islet transplantation has been demonstrated in principle by the Edmonton studies, however it faces two major obstacles which prevent it from helping all Insulin Dependent diabetics, namely 1) the need for continuous immunosuppressive drugs to prevent rejection of the transplanted human islet cells and 2) the lack of human donor tissue.

Islet Sciences is dedicated to overcoming these obstacles by commercializing porcine islets, which are in abundant supply, and encapsulating them to avoid an immune rejection and the need for toxic immunosuppression therapy.

INFUSION TECHNOLOGY

Proprietary Islet Maturation

A vialed suspension of microencapsulated porcine islets for injection into the abdominal cavity. Islet Sciences-P will be a ready-to-use formulation that will require very little preparation by the transplant surgeon. IS-P is designed to improve microencapsulated islet cell viability and functionality at several points in the preparation of this suspension. We believe our cell handling techniques substantially increase the longevity and functionality of the encapsulated islet cells.

INVESTOR INFORMATION

Islet Science seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents. Islet Sciences is traded on the OTC under the ticker symbol ISLT.

READ MORE >>